Asthma is costly for MCOs

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.313, 2001-01, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bambuterol is as effective as, but less costly than, salmeterol in the treatment of asthma

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 244, 2000-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Is quality of care sacrificed with MCOs' financial incentives?

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 400, 2003-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

What treatments are selected by physicians and MCOs?

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 623, 2011-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Physicians and MCOs don't always see eye to eye

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 624, 2011-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Patient copays expanded to curb rising costs in US MCOs

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 266, 2000-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite